Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 3
2020 4
2021 4
2022 5
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M; French Network of Regional Pharmacovigilance Centers. Allouchery M, et al. J Immunother Cancer. 2020 Dec;8(2):e001622. doi: 10.1136/jitc-2020-001622. J Immunother Cancer. 2020. PMID: 33428586 Free PMC article.
Antituberculosis Drug-Associated DRESS: A Case Series.
Allouchery M, Logerot S, Cottin J, Pralong P, Villier C, Ben Saïd B; French Pharmacovigilance Centers Network and the French Investigators for skin adverse reactions to drugs. Allouchery M, et al. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1373-1380. doi: 10.1016/j.jaip.2017.11.021. Epub 2017 Dec 20. J Allergy Clin Immunol Pract. 2018. PMID: 29274824
Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.
Morice PM, Genthon A, Boyer T, Bihan K, Mahé J, Sourisseau A, Peyrouzet H, Miremont G, Lepelley M, Stefani L, Gaboriau L, Rocher F, Aquaronne D, Le Beller C, Allouchery M, Azzouz B, Massy N, Alt-Tebacher M, Simand C, Herbrecht R, Chrétien B, Dolladille C, Chantepie S, Alexandre J. Morice PM, et al. Among authors: allouchery m. Br J Haematol. 2022 Feb;196(3):787-793. doi: 10.1111/bjh.17863. Epub 2021 Oct 5. Br J Haematol. 2022. PMID: 34611896 No abstract available.
Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database.
Martin M, Nguyen HM, Beuvon C, Bene J, Palassin P, Atzenhoffer M, Rouby F, Sassier M, Pérault-Pochat MC, Roblot P, Allouchery M, Puyade M; French Network of Regional Pharmacovigilance Centers. Martin M, et al. Among authors: allouchery m. Cancers (Basel). 2022 Oct 14;14(20):5030. doi: 10.3390/cancers14205030. Cancers (Basel). 2022. PMID: 36291814 Free PMC article.
Patterns of use and safety of ibrutinib in real-life practice.
Allouchery M, Tomowiak C, Guidez S, Delwail V, Delaunay P, Lafay-Chebassier C, Salvo F, Pérault-Pochat MC. Allouchery M, et al. Br J Clin Pharmacol. 2021 Mar;87(3):895-904. doi: 10.1111/bcp.14440. Epub 2020 Jul 5. Br J Clin Pharmacol. 2021. PMID: 32559327 Free article.
15 results